atorvastatin has been researched along with Chronic Kidney Diseases in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 34 (80.95) | 24.3611 |
| 2020's | 8 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, AR; Dunning, SC; Fine, DM; Grams, ME; Inker, LA; Nolin, TD; Sang, Y; Shin, JI; Surapaneni, A | 1 |
| Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A | 1 |
| Ahlström, C; Dong, J; Elebring, M; Huang, Y; Lundahl, A; Någård, M; Prieto Garcia, L; Sjögren, E; Tang, W; Vildhede, A | 1 |
| Duan, Q; Peng, X; Wang, J; Wang, Z; Xia, F | 1 |
| Atighi, E; Babapour, B; Hosseninia, S; Mohammadi Kebar, S | 1 |
| Archer, DR; Ataga, KI; Cai, J; Caughey, MC; Derebail, VK; Elsherif, L; Hinderliter, AL; Maitra, P; Pollock, DM; Pollock, JS; Wichlan, D; Wogu, AF | 1 |
| de Zeeuw, D; Heerspink, HJL; Kroonen, MYAM; Stevens, J | 1 |
| Cummings, JL; Ginsberg, HD; Johansson, JO; Kalantar-Zadeh, K; Kulikowski, E; Nicholls, SJ; Ray, KK; Schwartz, GG; Sweeney, M; Toth, PP; Wong, N | 1 |
| Chang, D; Ghelani, H; Inampudi, V; Nammi, S; Razmovski-Naumovski, V | 1 |
| Kasahara, M; Kuwabara, Y; Nakao, K; Ueshima, K; Yasuno, S | 1 |
| Ahn, S; Ha, J; Min, SK; Oh, GT; Song, EJ | 1 |
| Hoogeveen, RM; Kaiser, Y; Kroon, J; Moens, SJB; Stroes, ESG; Verberne, HJ; Verweij, SL; Vogt, L | 1 |
| Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD | 1 |
| Geng, Q; Guo, L; Liu, Y; Liu, Z; Ma, H; Wang, P; Xie, H; Zhan, H; Zhang, G | 1 |
| Chen, J; Dai, J; Mao, W; Qiu, Y; Wang, Z; Xu, H; Xu, X; Zhou, X | 1 |
| Masajtis-Zagajewska, A; Nowicki, M | 1 |
| Mittal, A; Nand, N | 1 |
| Knap, N; Lizakowski, S; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB | 2 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Coombes, JS; Fassett, RG; Geraghty, DP | 1 |
| Campese, VM | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Chngrian, GV; Mysyshin, MB; Salomenchuk, TN; Semegen-Bodak, KV; Slaba, nA; Slabyĭ, OM | 1 |
| Chen, JY; Chen, PY; Duan, CY; Li, HL; Li, LW; Liu, Y; Liu, YH; Luo, JF; Tan, N; Zhou, YL | 1 |
| Hamza, M; Shehata, M | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Deedwania, PC; Fayyad, RS; Laskey, RE; Stone, PH; Wilson, DJ | 1 |
| Billings, FT; Brown, NJ; Byrne, JG; Hendricks, PA; Petracek, MR; Schildcrout, JS; Shi, Y | 1 |
| Gutjahr-Lengsfeld, LJ; Krane, V; Mann, JF; März, W; Schmidt, KR; Swoboda, F; Wanner, C | 1 |
| Breazna, A; Deedwania, PC; LaRosa, JC; Messig, M; Shepherd, J; Wenger, NK; Wilson, DJ | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Manzone, C; Micheletti, C; Tedeschi, D; Toso, A | 1 |
| Aleksandrowicz, E; Larczyński, W; Lysiak-Szydłowska, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Ziętkiewicz, M | 1 |
| Baigorria, ST; Eynard, AR; Fiore, MC; García, NH; Juncos, LA; Juncos, LI; Martín, FL; Pasqualini, ME | 1 |
| Babazono, T; Fujimoto, A; Imamoto, M; Kasahara, M; Kimura, G; Koya, D; Nakao, K; Sato, T; Tanaka, S; Ueshima, K; Yasuno, S | 1 |
| Allolio, B; Bidlingmaier, M; Blouin, K; Drechsler, C; Fassnacht, M; Hammer, F; Krane, V; März, W; Pilz, S; Ritz, E; Schönfeld, S; Tomaschitz, A; Wanner, C | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
5 review(s) available for atorvastatin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis.
Topics: Acute Kidney Injury; Aged; Atorvastatin; Cardiac Catheterization; Comparative Effectiveness Research; Contrast Media; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Rosuvastatin Calcium; Treatment Outcome | 2019 |
Do statins play a role in renoprotection?
Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
Topics: Acute Kidney Injury; Atorvastatin; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
21 trial(s) available for atorvastatin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Preventive Effects of Nicorandil and Atorvastatin in Contrastinduced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Artery Angiography: A Double Blind, Randomized, Controlled Clinical Trial.
Topics: Atorvastatin; Coronary Angiography; Coronary Vessels; Humans; Nicorandil; Renal Insufficiency; Renal Insufficiency, Chronic | 2023 |
A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.
Topics: Aged; Albuminuria; Anemia, Sickle Cell; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; beta-Thalassemia; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyurea; Male; Middle Aged; Pilot Projects; Renal Circulation; Renal Insufficiency, Chronic; Sickle Cell Trait | 2019 |
Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Creatinine; Diabetes Complications; Female; Humans; Kidney Function Tests; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Rosuvastatin Calcium | 2019 |
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proteins; Quinazolinones; Renal Insufficiency, Chronic; Renin-Angiotensin System; Rosuvastatin Calcium; Stroke; Treatment Outcome | 2019 |
The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperlipidemias; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2020 |
Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study.
Topics: Aged; Anemia; Atorvastatin; Cross-Over Studies; Double-Blind Method; Female; Glomerular Filtration Rate; GPI-Linked Proteins; Hemochromatosis Protein; Hemoglobins; Hepcidins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Male; Metabolic Networks and Pathways; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Evaluation of Effect of Statins on Erythropoietin Resistance in Patients of Chronic Kidney Disease on Maintenance Haemodialysis.
Topics: Adult; Anemia; Atorvastatin; Erythropoietin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
[Isoprostanes - important marker of the oxidative stress estimation in patients with chronic kidney disease].
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Isoprostanes; Male; Middle Aged; Oxidative Stress; Protective Agents; Pyrroles; Renal Insufficiency, Chronic; Renin-Angiotensin System; Young Adult | 2013 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins | 2014 |
Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Renal Insufficiency, Chronic; Tasmania; Time Factors; Treatment Outcome | 2014 |
Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Epithelial Sodium Channels; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Renal Insufficiency, Chronic; Vascular Stiffness | 2014 |
[Antiatherogenic and nephroprotective efficacy of atorvastatin in patients with chronic renal disease of non-diabetic origin].
Topics: Anticholesteremic Agents; Atorvastatin; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Kidney Function Tests; Lipid Metabolism; Male; Middle Aged; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Topics: Aged; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Topics: Acute Kidney Injury; Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Coronary Artery Disease; Creatinine; Diabetic Nephropathies; Double-Blind Method; Egypt; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Protective Factors; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Renal Insufficiency, Chronic; Uric Acid | 2015 |
High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Aspartate Aminotransferases; Atorvastatin; Cardiac Surgical Procedures; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Postoperative Complications; Renal Insufficiency, Chronic | 2016 |
Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Surveys and Questionnaires; Time Factors | 2016 |
Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Creatinine; Female; Fluid Therapy; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Risk Factors | 2010 |
Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Topics: Adult; Atorvastatin; Cross-Over Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Pyrroles; Renal Insufficiency, Chronic | 2010 |
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Data Interpretation, Statistical; Disease Progression; Dyslipidemias; Endpoint Determination; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Research Design; Treatment Outcome | 2013 |
16 other study(ies) available for atorvastatin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.
Topics: Atorvastatin; Hematuria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proteinuria; Renal Insufficiency, Chronic; Rosuvastatin Calcium | 2022 |
Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.
Topics: Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2023 |
Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Computer Simulation; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Biological; Neoplasm Proteins; Renal Insufficiency, Chronic; Rosuvastatin Calcium | 2023 |
Atorvastatin reduces renal interstitial fibrosis caused by unilateral ureteral obstruction through inhibiting the transcriptional activity of YAP.
Topics: Animals; Atorvastatin; Fibrosis; Mice; Renal Insufficiency; Renal Insufficiency, Chronic; Ureteral Obstruction | 2023 |
Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.
Topics: Adenine; Animals; Atorvastatin; Kidney; Lipid Metabolism; Liver; Male; Protective Agents; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic | 2019 |
Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cytokines; Disease Models, Animal; Female; Lipid Metabolism; Mice; Mice, Knockout; Renal Insufficiency, Chronic; Sirolimus | 2021 |
Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.
Topics: Aged; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Female; Fluorodeoxyglucose F18; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Renal Insufficiency, Chronic; Risk Factors | 2021 |
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2017 |
The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Renal Insufficiency, Chronic; Simvastatin; Time Factors | 2017 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
The impact of pre-intervention rate of kidney function change on the assessment of CKD progression.
Topics: Aged; Atorvastatin; Biomarkers; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Recovery of Function; Renal Insufficiency, Chronic; Research Design; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Artery Disease; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Survival Rate; United States | 2016 |
Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Topics: Animals; Atorvastatin; Blood Pressure; Creatinine; Diet; Fatty Acids, Unsaturated; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Male; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium Chloride, Dietary | 2012 |
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Anticholesteremic Agents; Atorvastatin; Death, Sudden, Cardiac; Drug Synergism; Female; Heptanoic Acids; Humans; Hydrocortisone; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Young Adult | 2013 |